title: Relationship between plasma phospholipid polyunsaturated fatty acid composition and bone disease in renal transplantation.
abstract: To investigate the relationship between polyunsaturated fatty acid (PUFA) and bone metabolism in renal transplant patients, plasma phospholipid (PP) PUFA levels, biochemical markers of bone turnover and bone mineral density (BMD) were determined in 22 recipients of a first renal allograft at baseline and after a mean 24.4 month follow-up. A significant increase in PP n-3 PUFA content, in the [n-3 PUFA/ arachidonic acid] ratio and in BMD values was observed, as well as a close correlation between the increase in PP n-3 PUFA content and femoral neck BMD. Multivariate regression analysis showed that BMD improvement was positively related to PP n-3 PUFA variation and baseline PP eicosapentaenoic acid levels, and negatively to PP arachidonic acid modification. Tacrolimus- versus cyclosporine-treated patients demonstrated a significant increase in femoral neck BMD and PP n-3 PUFA content. This is the first longitudinal study showing a link between PP-PUFA composition and bone disease in renal transplantation.
authors.affiliation: Department of Medical and Surgical Sciences, University of Padova, and Central Laboratory, University Hospital of Padova, Italy. bruno.baggio@unipd.it
authors.forename: Bruno
authors.initials: B
authors.lastname: Baggio
authors.forename: Alessandro
authors.initials: A
authors.lastname: Budakovic
authors.forename: Alberto
authors.initials: A
authors.lastname: Ferraro
authors.forename: Simone
authors.initials: S
authors.lastname: Checchetto
authors.forename: Giovanna
authors.initials: G
authors.lastname: Priante
authors.forename: Estella
authors.initials: E
authors.lastname: Musacchio
authors.forename: Enzo
authors.initials: E
authors.lastname: Manzato
authors.forename: Martina
authors.initials: M
authors.lastname: Zaninotto
authors.forename: Maria-Cristina
authors.initials: MC
authors.lastname: Maresca
mesh_terms: D000328:Adult; D016718:Arachidonic Acid / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D001847:Bone Diseases / Q000209:etiology*; D016723:Bone Remodeling; D016572:Cyclosporine / Q000627:therapeutic use; D015525:Fatty Acids, Omega-3 / Q000097:blood; D005231:Fatty Acids, Unsaturated / Q000097:blood*; D005260:Female; D005272:Femur Neck / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood*; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D015525:Fatty Acids, Omega-3; D005231:Fatty Acids, Unsaturated; D007166:Immunosuppressive Agents; D010743:Phospholipids; D016718:Arachidonic Acid; D016572:Cyclosporine; D016559:Tacrolimus